… on Lung Cancer (WCLC) demonstrates that monitoring circulating tumor DNA (ctDNA) can refine and personalize the use of …

… 2021, 9 a.m. GMT/10 a.m. CDT/11 a.m. EDT) --Pre-treatment circulating tumor (ct)DNA levels more accurately predicted long-term survival than …

… PD-L1 inhibition overcomes T-cell suppression at the tumor; and chemotherapy causes tumor cell death and antigen … molecularly characterized via sequencing of tumor tissue DNA and/or circulating tumor DNA samples. Progression free survival and …

… Barcelona— Tumor mutational burden was not significantly associated … Garassino from theFondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Dr. Garassino presented this new data … by whole-exome sequencing of tumor and matched normal DNA. The clinical utility of TMB on outcomes was assessed …

… complex malignancy. Liquid biopsy, and especially plasma ctDNA, can be used in many clinical settings where tissue is … that IASLC is in the forefront in this arena.” Although tumor tissue is historically the gold standard biospecimen … biopsy approach includes a variety of methodologies for circulating analytes. From a clinical point of view, plasma …

… a powerful tool that can determine the patient’s molecular tumor profile in order to determine the best therapeutic … applied as an alternative to tissue testing in cases where tumor testing is not possible or tissue is not adequate,” … rebiopsies. In this context, the isolation of tumor-derived DNA, RNA and cells from the peripheral circulation (a …

… reported data from the KEYNOTE 021 trial that showed antitumor activity for pembrolizumab plus platinum-based … and pemetrexed or carboplatin and pemetrexed alone. Tumor mutational burden was determined by whole exome sequencing of tumor and matched normal DNA. Langer and the KEYNOTE 021 researchers were able to …

… specific cancer’s growth and progression. Patients whose tumors harbor certain, specific molecular alterations may be … EGFR  T790M in relapse may be done by biopsy or cell-free circulating DNA.  However cell-free DNA is not appropriate for initial …

… predictive biomarkers, which may enable better targeting of tumor characteristics. Its aims to accelerate development of … and novel diagnostic approaches – like the detection of circulating tumor DNA in blood samples – to identify patients with a poor …

… safety. Minimal residual disease (MRD) was assessed using circulating tumor DNA (Guardant Reveal). Mariano Provencio, MD, PhD, Hospital …

… demonstrated manageable safety and early signs of anti-tumor activity in patients with relapsed small cell lung … a humanized anti-DLL3 IgG1 monoclonal antibody linked to a DNA topoisomerase I inhibitor via a cleavable linker. Given …